Last reviewed · How we verify

NCT07126132

Hpx•apoB Product as a Biomarker for Coronary Artery Disease

Completed Last updated 17 August 2025
What this trial tests

trial testing Coronary Angiography in Coronary Artery Disease in 460 participants. Completed in 31 December 2023.

Timeline
1 January 2019
Primary endpoint
31 December 2023
31 December 2023

Quick facts

Lead sponsorShiyan City Renmin Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment460
Start date1 January 2019
Primary completion31 December 2023
Estimated completion31 December 2023
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Shiyan City Renmin Hospital

Who can join

18 and older, any sex, with Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This was a single-center, cross-sectional study designed to investigate a novel composite biomarker, the Hemopexin-Apolipoprotein B (Hpx•apoB) product, for its association with coronary artery disease (CAD). The study aimed to determine if the Hpx•apoB product could serve as an independent predictor for the presence and severity of CAD and to evaluate its incremental value in improving risk stratification when added to existing clinical risk models.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Coronary Angiography

Trials testing the same drug.

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

Other Shiyan City Renmin Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07126132.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing